FARA is issuing a request for proposals (RFP) to support clinical drug development programs in Friedreich’s ataxia (FRDA) by promoting the discovery of technologies to measure frataxin or surrogates of frataxin in inaccessible and disease relevant tissues.
This RFP supports the discovery and validation of non-invasive and quantitative methodologies to measure the following in FRDA affected tissues (brain, spinal cord or heart):
- Frataxin protein levels
- Biochemical activities dependent on/downstream of frataxin function that can be surrogates of frataxin in inaccessible tissues
Allowed budget will depend on stage and scope of research.
FARA will consider proof of concept and high-risk proposals, without preliminary data, provided they show a strong rationale for the proposed use and development of such biomarkers.
Informal inquiries regarding study relevance and interest to FARA are welcome and should be directed to
Please click below to submit a Letter of Intent.The LOI submission deadline is December 1, 2021.